← Về thư mục
📄 / / profiles / r-and-d / raw_evidence / OpenAI4S / skills / bioskills / bio-epidemiological-genomics-amr-surveillance / SKILL.md

name: bio-epidemiological-genomics-amr-surveillance description: Detects acquired antimicrobial-resistance determinants and chromosomal point-mutation resistance in bacterial assemblies using AMRFinderPlus, ResFinder 4.0 (acquired + PointFinder), CARD-RGI, abritAMR, staramr, and species-specific callers (TB-Profiler, Mykrobe). Harmonises cross-tool output via hAMRonization, contextualises determinants with mobile-genetic-element annotation (MOB-suite, PlasmidFinder, MobileElementFinder, ICEberg), predicts phenotype against EUCAST or CLSI breakpoints, and translates calls into WHO GLASS reporting categories. Use when screening clinical or surveillance isolates for AMR, distinguishing acquired vs intrinsic vs point-mutation resistance, calling rpoB / katG / pncA / gyrA / mgrB mutations, reconciling AMRFinderPlus vs RGI vs ResFinder disagreement, contextualising carbapenemases or mcr alleles on plasmids, predicting susceptibility from genotype against the WHO Mtb 2nd-edition catalogue, or building a hAMRonized multi-lab AMR surveillance pipeline. origin: openai4s category: bioskills/epidemiological-genomics metadata: tool_type: mixed primary_tool: AMRFinderPlus third_party: name: GPTomics/bioSkills repository: https://github.com/GPTomics/bioSkills commit: d91ed3d563019e649dc854c56ccd62551359488a license: MIT

Version Compatibility

Reference examples tested with: ncbi-amrfinderplus 4.0+, resfinder 4.5+, rgi 6.0+ (CARD 3.3+), abritamr 1.0.14+, staramr 0.10+, hamronization 1.1+, tb-profiler 6.2+, mykrobe 0.13+, mob_suite 3.1+, plasmidfinder 2.1+, MobileElementFinder 1.0+, pandas 2.2+, BioPython 1.84+.

Before using code patterns, verify installed versions match. If versions differ: - Python: pip show <package> then help(module.function) to check signatures - CLI: <tool> --version then <tool> --help to confirm flags - AMRFinderPlus: amrfinder --list_organisms for the current --organism catalogue - WHO Mtb catalogue: tb-profiler list_db and verify the bundled WHO edition - AMR database freshness: amrfinder -u (NCBI ReferenceGeneCatalog) and tb-profiler update_tbdb

If a flag or column name does not match (--species vs --organism, barcode_build vs barcode-build), introspect the installed package rather than retrying. AMRFinderPlus, RGI, and ResFinder all renamed columns between major releases.

AMR Surveillance

"What antibiotic-resistance determinants are in this assembly, and what susceptibility do they imply?" -> Combine acquired-gene detection, chromosomal point-mutation calling, mobile-element context, and curated phenotype mapping into a single per-isolate report fit for surveillance or clinical handover. Tool choice is determined by species (Mtb needs TB-Profiler, not AMRFinderPlus), reporting standard (WHO GLASS vs CARD vs in-house), and whether mobility matters (carbapenemase outbreak: yes; routine ESBL screen: less so).

The Single Most Important Modern Insight -- Acquired AMR detection is not species-agnostic

A pan-species AMRFinderPlus run misses chromosomal point-mutation resistance because the point-mutation panels are species-specific and activated only when --organism is set. Running amrfinder -n mtb.fa without --organism returns "no AMR detected" on an XDR-TB genome because AMRFinderPlus has no Mtb organism mode -- the user must switch tools (TB-Profiler or Mykrobe + WHO 2nd-edition catalogue). Similarly, Salmonella gyrA T83I, Klebsiella mgrB inactivation, and E. coli QRDR mutations are silent without --organism Salmonella / Klebsiella_pneumoniae / Escherichia. For any cross-tool surveillance pipeline, AMRFinderPlus with --organism MUST be paired with a species-specific second tool (TB-Profiler for Mtb; ResFinder 4.0 with -s 'species' for PointFinder coverage; hAMRonization to merge). Andersson et al. Nat Rev Microbiol 17:479 (2019) further notes that heteroresistance at 0.1-1% allele frequency is widespread and invisible to default variant callers, compounding the failure mode for any single-tool workflow.

Algorithmic Taxonomy

Tool Mechanism Inputs Output Strength Fails when
AMRFinderPlus (Feldgarden 2021 Sci Rep 11:12728) Curated HMM + BLAST against NCBI ReferenceGeneCatalog; per-gene cutoffs assembly or protein gene + class + element-type Gene-family-aware (catches divergent variants); built-in species point-mutation panels No Mtb mode; reports intrinsic genes unless --organism set
ResFinder 4.0 (Bortolaia 2020 J Antimicrob Chemother 75:3491) BLAST against ResFinder DB (acquired) + PointFinder DB (chromosomal mutations) per species assembly or reads gene + predicted phenotype (S/I/R) Phenotype prediction tied to CLSI/EUCAST Requires explicit -s 'species' for PointFinder; default 90/60 cutoffs hide divergent variants
CARD-RGI (Alcock 2023 NAR 51:D690) BLAST + HMM against CARD; tiers Perfect / Strict / Loose assembly or protein ARO ontology term, model-type (homolog / variant / overexpression / knockout / rRNA) Mechanism-resolved (operons modelled); ARO ontology is curated Loose tier produces many false positives; default Strict+Perfect misses real variants in non-model organisms
abritAMR (Sherry 2023 Nat Commun 14:60) AMRFinderPlus wrapper + drug-class classifier; ISO-certified for clinical use assembly gene + drug class First ISO-certified AMR pipeline; accredited reporting categories Limited to AMRFinderPlus's underlying gene panel
staramr ResFinder + PointFinder + PlasmidFinder + MLST in one pipeline assembly combined report One-shot Salmonella / E. coli / Campylobacter surveillance Default organism handling can hide point mutations; verify each component version
TB-Profiler (Phelan 2019 Genome Med 11:41) Maps reads or assembly against H37Rv + WHO catalogue + Coll/Napier lineage barcode reads or assembly per-drug R/R-interim/Uncertain/S + lineage WHO 2nd-edition catalogue integration; lineage call; heteroresistance from allele frequency Hardcoded to MTBC; older bundled DB may predate current WHO edition
Mykrobe (Hunt 2019 Wellcome Open Res 4:191) k-mer presence/absence against curated panel reads species + AMR per drug k-mer-fast; cross-checks TB-Profiler; supports Mtb, S. aureus, Salmonella, gonorrhoea Panel may lag WHO catalogue; check --panel
hAMRonization (PHA4GE) Format converter to PHA4GE schema per-tool TSV unified TSV/JSON Cross-tool comparison; surveillance harmonisation Mandatory metadata fields differ per tool subparser

Decision Tree by Scenario

Scenario Recommended Why wrong choices fail
Routine screen of an E. coli / Klebsiella / Salmonella assembly for acquired AMR + point mutations AMRFinderPlus with --organism Escherichia / Klebsiella_pneumoniae / Salmonella + --plus Without --organism: no PointFinder panel, fluoroquinolone QRDR mutations missed; intrinsic-gene noise in Klebsiella
M. tuberculosis drug-resistance prediction TB-Profiler interpreted via WHO 2nd-edition catalogue, Mykrobe as cross-check on R/XDR isolates AMRFinderPlus has no Mtb organism mode; ResFinder PointFinder lacks the full WHO catalogue; tool defaults silently call Group 3 mutations as "susceptible"
Predict S/I/R phenotype, not gene presence ResFinder 4.0 OR abritAMR; document EUCAST or CLSI breakpoint year AMRFinderPlus reports presence only; mapping presence -> phenotype needs curated rules
Carbapenemase outbreak: is the gene mobile? AMRFinderPlus -> MOB-suite (mob_recon + mob_typer) -> cross-reference; long-read or hybrid assembly recommended PlasmidFinder alone gives replicon type but not gene-plasmid linkage; short-read draft assemblies fragment plasmid contigs and lose context
Cross-laboratory surveillance reporting Pass per-tool output through hAMRonization to PHA4GE schema; populate analysis_software_version and reference_database_version Raw cross-tool comparison is meaningless (CARD ARO vs ResFinder name vs NCBI ReferenceGeneCatalog)
Novel-variant surveillance (emergence) AMRFinderPlus (HMM, gene-family-aware) OR CARD-RGI with Loose-tier manual review abricate's 80/80 defaults reject divergent family members; pure-BLAST defaults silently miss novel mcr / OXA sub-variants
Quantitative AMR from metagenomic reads AMRPlusPlus / DeepARG / ARGs-OAP normalised to 16S; report "ARG abundance" NOT "resistance" Assembly-based tools fail on short reads; reporting environmental ARG counts as "resistance" inherits the environmental-resistome critique that homolog presence is not phenotypic resistance
Colistin resistance in Klebsiella / Enterobacter / Salmonella mcr-1 to mcr-10 acquired (AMRFinderPlus; mcr-1 originally Liu 2016 Lancet Infect Dis 16:161) + mgrB / pmrAB / phoPQ point mutations (--organism Klebsiella_pneumoniae) + phenotypic confirmation for mcr-9/10 mcr-9 / mcr-10 frequently report without elevated MIC; treating mcr presence as "colistin-R" triggers infection control unnecessarily
WHO GLASS submission hAMRonization -> drug-class mapping -> EUCAST/CLSI breakpoint interpretation; record breakpoint year Gene-level reporting without class mapping cannot populate GLASS categories

Methodology evolves rapidly; before a high-stakes outbreak report, web-search "AMRFinderPlus organism modes 2026" and confirm the WHO Mtb catalogue edition currently bundled in TB-Profiler.

AMRFinderPlus With Species Mode

Goal: Produce a per-isolate AMR report including acquired genes, species-specific chromosomal point mutations, stress/virulence elements, and per-hit method and coverage metadata for downstream harmonisation.

Approach: Run amrfinder with -n for nucleotide assembly, --organism to activate the species-specific point-mutation panel, --plus to include stress / virulence / heat / metal, and --report_all when truncated-gene visibility matters. Pin the database via amrfinder -u -> verify --db matches a recorded date.

DB=$(amrfinder -V | grep -i database | awk '{print $NF}')

amrfinder \
    -n assembly.fa \
    --organism Klebsiella_pneumoniae \
    --plus \
    --threads 8 \
    -o sample.amrfinder.tsv

echo "DB version: ${DB}" >> sample.amrfinder.tsv

Column semantics worth inspecting: Element type (AMR / POINT / VIRULENCE / STRESS / etc.), Method (EXACTX / PARTIAL_CONTIG_END / HMM / etc. -- partial-contig hits flag assembly fragmentation), % Coverage of reference sequence, % Identity to reference sequence, Class / Subclass (drug-class summary). Method = PARTIAL_CONTIG_END is the smoking gun for plasmid-context fragmentation -- consider long-read confirmation.

TB-Specific Workflow

Goal: Generate a WHO-catalogue-aligned drug-resistance report for M. tuberculosis covering all 13 first-line + second-line + new/repurposed drugs, with lineage assignment via the Coll/Napier MTBC barcode (90-SNP version) and explicit handling of Group 3 (Uncertain) mutations.

Approach: TB-Profiler primary (it bundles the WHO catalogue and reports the Walker 2022 / 2023 association grouping); Mykrobe as an orthogonal cross-check on any R / XDR call that will drive treatment. NEVER collapse Group 3 mutations to "susceptible" -- the WHO catalogue's tiered scoring is load-bearing for clinical handover.

tb-profiler update_tbdb

tb-profiler profile \
    -1 reads_R1.fq.gz \
    -2 reads_R2.fq.gz \
    -p sample \
    --txt --csv --pdf \
    --dir tbprofiler_out

mykrobe predict \
    --sample sample \
    --species tb \
    --output sample.mykrobe.json \
    --format json \
    reads_R1.fq.gz reads_R2.fq.gz

Allix-Béguec et al. (CRyPTIC) NEJM 379:1403 (2018) established >99% negative predictive value for first-line drugs and is the basis for WGS-only DST policies; the same study showed sensitivity remains lower for bedaquiline, delamanid, linezolid, and clofazimine, so phenotypic DST is still required for second-line and new/repurposed agents in MDR/XDR-TB workups. The WHO 2023 catalogue (Walker et al. Lancet Microbe 3:e265, 2022 for the 2021 edition methodology; 2023 second edition data) grades each mutation Group 1 / Group 2 (Associated -- interim) / Group 3 (Uncertain) / Group 4 (Not Associated -- interim) / Group 5 (Not Associated). Reporting Group 3 as "S" actively misleads clinicians.

hAMRonization for Cross-Tool Reporting

Goal: Convert per-tool AMR output (AMRFinderPlus, ResFinder, RGI, abricate, staramr, ARIBA, TB-Profiler, Mykrobe) to the PHA4GE schema so a multi-laboratory or multi-tool surveillance dataset is comparable.

Approach: Invoke hamronize <tool> per input with mandatory provenance metadata (--analysis_software_version, --reference_database_version, --input_file_name), then hamronize summarize to merge.

hamronize amrfinderplus \
    --analysis_software_version 4.0.3 \
    --reference_database_version 2025-02-01.1 \
    --input_file_name sample.amrfinder.tsv \
    sample.amrfinder.tsv > sample.hamr.tsv

hamronize resfinder \
    --analysis_software_version 4.5.0 \
    --reference_database_version 2024-12-15 \
    --input_file_name sample.resfinder.json \
    sample.resfinder.json > sample.resfinder.hamr.tsv

hamronize summarize -t tsv -o cohort.hamr.tsv per_sample_hamr/*.tsv

Default reporting ontology for public-health output is NCBI ReferenceGeneCatalog. Two consequences: (1) CARD ARO terms need translation; (2) any custom gene additions need a corresponding NCBI accession before they appear in the harmonised stream.

Mobile-Genetic-Element Context

Goal: Determine whether a clinically actionable AMR gene (carbapenemase, mcr, ESBL) sits on a chromosome, a plasmid (and which incompatibility group / cluster), an integrative-conjugative element, or a transposon -- because "gene present" tells the infection-control team nothing about transmissibility.

Approach: Reconstruct plasmids from the assembly with MOB-suite mob_recon; type each plasmid with mob_typer; cross-reference AMR-gene coordinates against the plasmid contig list; annotate IS elements / integrons with MobileElementFinder. For surveillance-grade plasmid resolution, prefer long-read (R10.4.1 Q20+) or hybrid assemblies -- short-read draft assemblies routinely fragment plasmid contigs.

mob_recon \
    --infile assembly.fa \
    --outdir mob_out/ \
    --num_threads 4

mob_typer \
    --infile mob_out/plasmid_AA001.fasta \
    --out_file mob_out/plasmid_AA001.typed.tsv

mefinder find \
    --contig assembly.fa \
    --out mef_out/sample \
    --threads 4

Document MOB-suite version explicitly: v2 and v3 cluster codes are non-interoperable, and v3.1+ adds MGE reporting. Across longitudinal surveillance crossing the v2 -> v3 boundary, the same plasmid receives different cluster IDs and appears spuriously "novel".

Per-Method Failure Modes

AMRFinderPlus run pan-species on a Mycobacterium tuberculosis assembly

Trigger: amrfinder -n mtb.fa without --organism; AMRFinderPlus has no Mtb organism mode in any v4.x release.

Mechanism: The species-specific point-mutation panels are activated only when a recognised --organism is passed. Mtb resistance is overwhelmingly chromosomal point mutation (rpoB / katG / inhA / pncA / embB / gyrA / rrs). With no panel active, none of these are called.

Symptom: Empty AMR table on a phenotypically MDR/XDR isolate; lineage barcode not reported (AMRFinderPlus does not call MTBC lineage).

Fix: Switch tools. Use TB-Profiler (preferred -- bundles WHO catalogue + Coll/Napier barcode) or Mykrobe; the AMRFinderPlus catalogue does not cover MTBC.

OXA-48-like family collapsed to a single bucket

Trigger: Default per-isolate summarisers report the gene family (bla_OXA-48-like) rather than the allele (bla_OXA-244).

Mechanism: OXA-48 (potent carbapenemase), OXA-181 (Thr213Ala -- similar activity, different plasmid), OXA-232 (Arg214Ser -- reduced carbapenemase activity), and OXA-244 (Arg214Gly -- weakest, often phenotypically susceptible to ertapenem) share >95% identity. Pipelines that report family-level summary erase the clinically actionable variant identity.

Symptom: Surveillance report says "OXA-48-like detected", phenotype is borderline ertapenem-susceptible / meropenem-susceptible, clinical team is confused about whether ceftazidime-avibactam is needed.

Fix: Report the allele explicitly; never collapse to family. AMRFinderPlus reports the allele in Gene symbol -- preserve it through hAMRonization rather than summarising.

IS-element-mediated derepression invisible to gene-presence pipelines

Trigger: Phenotypic high-level AmpC hyperproduction in Enterobacter cloacae complex / Citrobacter freundii; or KPC over-expression on Tn4401b (100-bp promoter deletion).

Mechanism: Resistance is mediated by ISEcp1 / IS26 / IS10 insertion upstream of the ampC promoter producing a strong hybrid promoter, or by Tn4401 variant. Gene presence is unchanged. Short-read assemblies fragment IS elements and collapse repeats; promoter context is lost. AMRFinderPlus / RGI / ResFinder report the gene; the regulatory configuration is not annotated.

Symptom: AMR pipeline output identical for wild-type ampC carrier and the hyperproducer; clinical phenotype is divergent.

Fix: Long-read (Nanopore R10.4.1 Q20+ or PacBio HiFi) or hybrid assembly with explicit promoter-context inspection. For Tn4401 variant typing, manual blast of the transposon region. Tools that automate this are emerging but not yet a default in surveillance pipelines.

Heteroresistance below default variant-caller thresholds

Trigger: Routine Illumina WGS-AMR pipeline on a clinical isolate; resistance variant appears at 1-5% allele frequency.

Mechanism: Heteroresistance -- clonal subpopulations carrying resistance at 0.1-1% (Andersson, Nicoloff, Hjort Nat Rev Microbiol 17:479, 2019) -- is widespread and clinically meaningful (treatment failure under antibiotic pressure). Default variant callers (bcftools, lofreq default -q 20, GATK HaplotypeCaller) require minor-allele frequency of typically 10-20% to call. Assembly-based pipelines (AMRFinderPlus on assembly) collapse minor variants entirely.

Symptom: Surveillance pipeline calls "S" but clinical failure under therapy; subsequent sampling reveals high-level resistance.

Fix: For clinically critical drugs, supplement assembly-based AMR with deep-read variant calling at lower MAF thresholds (lofreq with -q 13 -a 0.01), or use targeted deep-amplicon sequencing. TB-Profiler reports allele frequency for resistance calls -- inspect for heteroresistance routinely.

WHO Mtb Group 3 mutations silently called "susceptible"

Trigger: TB-Profiler / Mykrobe run on an Mtb isolate carrying a mutation graded Group 3 (Uncertain) in the WHO catalogue.

Mechanism: Tools translate Group 3 calls to "no resistance prediction" in their summary; downstream summarisers and clinical handover forms collapse "no prediction" to "S". The Walker 2022 Lancet Microbe catalogue methodology explicitly separates Group 3 (Uncertain) from Group 4/5 (Not Associated) for exactly this reason.

Symptom: Patient treated as drug-susceptible; clinical failure; retrospective inspection finds Group 3 mutation that should have triggered phenotypic DST.

Fix: Read TB-Profiler JSON output, NOT the simplified TSV. Report Group 3 mutations explicitly with "uncertain significance -- phenotypic DST recommended". This is widely under-communicated in surveillance pipelines.

fosA / efflux-regulator hits overcalled as resistance

Trigger: Chromosomal fosA in Klebsiella pneumoniae / Enterobacter / Serratia reported as "fosfomycin resistant" by ResFinder / AMRFinderPlus.

Mechanism: Chromosomal fosA confers low-level fosfomycin resistance below the EUCAST clinical breakpoint (32 mg/L for urinary isolates). Treating chromosomal-fosA E. coli as fosfomycin-resistant withholds an oral option for uncomplicated UTI unnecessarily.

Symptom: All K. pneumoniae isolates flagged "fosfomycin-R" regardless of plasmid context or phenotype.

Fix: AMRFinderPlus with --organism Klebsiella_pneumoniae suppresses the intrinsic fosA report; verify the suppression worked. Cross-reference fosA hits with MOB-suite to determine plasmid context; only plasmid-borne or upregulated fosA should be reported as resistance.

Reconciliation: When AMR Tools Disagree

Pattern Likely cause Action
AMRFinderPlus calls bla_NDM-5; ResFinder calls bla_NDM-1 Allele assignment differs by reference database (NCBI ReferenceGeneCatalog vs ResFinder DB); both are within the NDM family Report the family + flag the allele discordance; for clinical handover prefer NCBI nomenclature, for legacy comparability prefer ResFinder
RGI calls mecA "Strict"; AMRFinderPlus calls "EXACTX" Tier semantics differ; both real hits Concordant resistance call -- harmonise via hAMRonization, use NCBI ReferenceGeneCatalog nomenclature
ResFinder reports a gene at 88% identity; AMRFinderPlus omits ResFinder default 90/60; AMRFinderPlus HMM cutoff stricter for that family Manual review; for novel-variant surveillance, AMRFinderPlus + Loose-tier RGI catches more
TB-Profiler and Mykrobe disagree on isoniazid Different curated panels; one may predate WHO 2nd edition Defer to TB-Profiler interpreted against WHO catalogue; manual blast of katG / inhA / fabG1
mcr-9 detected; phenotypic colistin MIC susceptible Expected -- mcr-9 frequently silent without IqrR / induction Report mcr-9 detection + susceptibility; do NOT trigger infection-control as if MCR-1
AMRFinderPlus Method=PARTIAL_CONTIG_END for a carbapenemase Assembly fragmentation at the plasmid edge Re-assemble with long reads or hybrid before reporting; the gene may be present in full
RGI calls a long list of "Loose" hits Non-model organism or distant lineage Manual curation of Loose hits -- discard generic homologs, retain those near canonical AMR-active residues

Quantitative Thresholds

Quantity Threshold Source / rationale
AMRFinderPlus default %identity per-gene curated (typically 90% global) Feldgarden 2021 Sci Rep 11:12728; HMM cutoff is gene-family-aware
AMRFinderPlus default %coverage 50% (alignment coverage) NCBI Reference; --report_all exposes partial hits
ResFinder default %id / %coverage 90% / 60% CGE convention; tighter than abricate
abricate default %id / %coverage 80% / 80% Too permissive for novel-variant surveillance
WHO Mtb Group 1 (Associated with R) High-confidence resistance call Walker 2022 Lancet Microbe 3:e265
WHO Mtb Group 3 (Uncertain) NOT "susceptible" -- phenotypic DST recommended Walker 2022 Lancet Microbe 3:e265; 2023 2nd edition data
Heteroresistance MAF 0.1-1% (deep amplicon detection) Andersson 2019 Nat Rev Microbiol 17:479
EUCAST fosfomycin urinary breakpoint 32 mg/L EUCAST clinical breakpoint tables (year-specific)
Variant MAF for routine WGS-AMR calling 10% (lofreq default), 20% (GATK default) Tool defaults; document per-pipeline

Common Errors

Error / symptom Cause Solution
AMRFinderPlus empty on TB assembly No Mtb --organism mode Switch to TB-Profiler / Mykrobe
AMRFinderPlus calls intrinsic fosA on Klebsiella --organism not set; intrinsic suppression off Always pass --organism for the species
--species flag rejected AMRFinderPlus uses --organism, not --species Use --organism Klebsiella_pneumoniae
Different gene names for same determinant across tools CARD ARO vs ResFinder vs NCBI ReferenceGeneCatalog Pass through hamronize
Method=PARTIAL_CONTIG_END on a clinically critical gene Assembly fragmentation Re-assemble with long reads / hybrid
hamronize rejects input as missing metadata --analysis_software_version not supplied Populate all mandatory PHA4GE fields per tool subparser
MOB-suite cluster codes don't match published outbreak paper v2 vs v3 incompatibility Re-run with matched MOB-suite version; document
Point-mutation panel coverage list flips between AMRFinderPlus minor releases DB schema change amrfinder --list_organisms and record the version
TB-Profiler bundled DB predates WHO 2nd edition DB not updated tb-profiler update_tbdb and verify catalogue edition

Anticipated Reviewer Pushback

Pushback Response
"Why AMRFinderPlus, not RGI?" AMRFinderPlus uses gene-family HMMs and NCBI-curated cutoffs that catch divergent novel variants without producing the Loose-tier noise of RGI; both are valid and hamronize lets the reviewer compare
"How were Group 3 WHO Mtb mutations handled?" Reported as "Uncertain significance -- phenotypic DST recommended"; not collapsed to S
"What about heteroresistance?" Read-based deep variant calling supplements assembly-based AMR for clinically critical drugs; report MAF
"Why not just trust ResFinder phenotype prediction?" EUCAST/CLSI breakpoint year must be documented; rule-based phenotype prediction inherits its curation as a hidden dependency. Pair with explicit gene + class reporting
"Why long-read assembly for AMR?" Short-read drafts fragment plasmid contigs and lose MGE / promoter context (e.g., ISEcp1 upstream of ampC; Tn4401 variants); long-read or hybrid is mandatory for any mobility / regulatory claim
"Why hAMRonization rather than tool-native outputs?" Cross-tool comparison requires schema unification; PHA4GE is the public-health consensus
"Was the intrinsic vs acquired distinction considered?" Yes -- --organism activates suppression of clinically inert intrinsic genes; reported separately

References